Novartis Inks Up-to-$5.7B Second Collaboration with Monte Rosa
Nearly a year after licensing Monte Rosa Therapeutics’ Phase II-bound autoimmune disease candidate MRT-6160, Novartis has agreed to…
Novartis, UNP, Launch Up-to-$1.8B+ Macrocyclic Peptide Partnership
Novartis will apply Unnatural Products (UNP)’s artificial intelligence (AI)-guided macrocyclic peptide platform to develop next-generation cardiovascular disease therapeutics,…
10x, Roche, Prognosys Sue Illumina over Spatial and Single-Cell Patents
10x Genomics’ facility at 5500 Stoneridge Mall Road Pleasanton, CA, one of the company’s three sites in the…